We are repeating our #BioMondeLIVE webinar on the Cost-Effectiveness of Debridement, today at 2pm 🕑 There is still time to register by completing this form 👉🏻 https://loom.ly/zldXuQ0 We will be analysing how cost effective various methods of wound debridement are, including a detailed focus on #LarvalTherapy. This information will aid your decision making when it comes to treatment pathway planning, and will provide advice on how to align those decisions to your clinical budgeting. #BioMonde #LarvalTherapy #WoundCare #Debridement
BioMonde UK’s Post
More Relevant Posts
-
Experienced commercial sales and marketing professional, a hands-on people leader with a successful track record of delivery. A 20 year heritage working at various operational levels.
The 𝗖𝗮𝗻𝗮𝗱𝗶𝗮𝗻 𝗖𝗼𝗻𝘀𝗲𝗻𝘀𝘂𝘀 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗩𝗲𝗻𝗼𝘂𝘀 𝗟𝗲𝗴 𝗨𝗹𝗰𝗲𝗿𝘀 (𝗩𝗟𝗨𝘀) is an interesting read, this guide incorporates the latest clinical research, including The geko® device which significantly improves healing rates and patient outcomes. If you would like to learn more about The geko® device please do get in touch.
Just published 📖 𝗖𝗮𝗻𝗮𝗱𝗶𝗮𝗻 𝗖𝗼𝗻𝘀𝗲𝗻𝘀𝘂𝘀 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗩𝗲𝗻𝗼𝘂𝘀 𝗟𝗲𝗴 𝗨𝗹𝗰𝗲𝗿𝘀 (𝗩𝗟𝗨𝘀) Recently published in Wound Care Canada and developed by a diverse panel of experts, the Consensus Statement is an up-to-date practical guide for health-care providers managing patients with VLUs. The guide incorporates the latest clinical research, including the use of muscle pump activators (MPAs,) such as The geko® device, which significantly improve healing rates and patient outcomes. Key highlights include diagnosis and assessment of VLU’s, VLU treatment strategies, effective wound care recommendations and emphasis on patient education and prevention of recurrence. Click here for the Consensus Statement: https://lnkd.in/eG5hducz And here to learn more about the geko device: https://lnkd.in/e-6tnSp2
-
Just published 📖 𝗖𝗮𝗻𝗮𝗱𝗶𝗮𝗻 𝗖𝗼𝗻𝘀𝗲𝗻𝘀𝘂𝘀 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗩𝗲𝗻𝗼𝘂𝘀 𝗟𝗲𝗴 𝗨𝗹𝗰𝗲𝗿𝘀 (𝗩𝗟𝗨𝘀) Recently published in Wound Care Canada and developed by a diverse panel of experts, the Consensus Statement is an up-to-date practical guide for health-care providers managing patients with VLUs. The guide incorporates the latest clinical research, including the use of muscle pump activators (MPAs,) such as The geko® device, which significantly improve healing rates and patient outcomes. Key highlights include diagnosis and assessment of VLU’s, VLU treatment strategies, effective wound care recommendations and emphasis on patient education and prevention of recurrence. Click here for the Consensus Statement: https://lnkd.in/eG5hducz And here to learn more about the geko device: https://lnkd.in/e-6tnSp2
-
Just published 📖 𝗖𝗮𝗻𝗮𝗱𝗶𝗮𝗻 𝗖𝗼𝗻𝘀𝗲𝗻𝘀𝘂𝘀 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗩𝗲𝗻𝗼𝘂𝘀 𝗟𝗲𝗴 𝗨𝗹𝗰𝗲𝗿𝘀 (𝗩𝗟𝗨𝘀) Recently published in Wound Care Canada and developed by a diverse panel of experts, the Consensus Statement is an up-to-date practical guide for health-care providers managing patients with VLUs. The guide incorporates the latest clinical research, including the use of muscle pump activators (MPAs,) such as The geko® device, which significantly improve healing rates and patient outcomes. Key highlights include diagnosis and assessment of VLU’s, VLU treatment strategies, effective wound care recommendations and emphasis on patient education and prevention of recurrence. Click here for the Consensus Statement: https://lnkd.in/eG5hducz And here to learn more about the geko device: https://lnkd.in/e-6tnSp2
-
Just published 📖 𝗖𝗮𝗻𝗮𝗱𝗶𝗮𝗻 𝗖𝗼𝗻𝘀𝗲𝗻𝘀𝘂𝘀 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗩𝗲𝗻𝗼𝘂𝘀 𝗟𝗲𝗴 𝗨𝗹𝗰𝗲𝗿𝘀 (𝗩𝗟𝗨𝘀) Recently published in Wound Care Canada and developed by a diverse panel of experts, the Consensus Statement is an up-to-date practical guide for health-care providers managing patients with VLUs. The guide incorporates the latest clinical research, including the use of muscle pump activators (MPAs,) such as The geko® device, which significantly improve healing rates and patient outcomes. Key highlights include diagnosis and assessment of VLU’s, VLU treatment strategies, effective wound care recommendations and emphasis on patient education and prevention of recurrence. Click here for the Consensus Statement: https://lnkd.in/eG5hducz And here to learn more about the geko device: https://lnkd.in/e-6tnSp2
-
Director Of Business Development at Target RWE Health Evidence Solutions | Real World Data | Real World Evidence | Healthcare Outcomes | Clinical Studies | Analytics | External Control Arms | PASS |
🎥 At #ACG2024, A. Sidney Barritt IV, MD, MSCR, presented compelling findings from the #TARGETNASH cohort on the real-world impact of treatments for #MASLD. These insights are helping us better understand #PatientOutcomes and the path forward for improved care. 🔗 Check out the full presentation now: https://lnkd.in/eTBJjZKP #LiverDisease #RealWorldEvidence #HealthcareInnovation #TargetRWE #ResearchImpact #ACG2024
▶️📈 Exciting Research from #TargetRWE at #ACG2024! A. Sidney Barritt IV, MD, MSCR, lead author and member of the #TARGETNASH steering committee, presented groundbreaking findings at the American College of Gastroenterology 2024 on the real-world impact of specific medications in patients with #MASLD. In this presentation, Dr. Barritt shares insights from the TARGET-NASH cohort, exploring the association between medication use and key #PatientOutcomes, including #Mortality and #DiseaseProgression. 🔍 Watch now to learn about the latest findings and their potential to change patient care: https://lnkd.in/gwUtRPVN #ClinicaResearch #LiverDisease #HealthcareInnovation #LiverResearch #RealWorldEvidence #RealWorldData
-
▶️📈 Exciting Research from #TargetRWE at #ACG2024! A. Sidney Barritt IV, MD, MSCR, lead author and member of the #TARGETNASH steering committee, presented groundbreaking findings at the American College of Gastroenterology 2024 on the real-world impact of specific medications in patients with #MASLD. In this presentation, Dr. Barritt shares insights from the TARGET-NASH cohort, exploring the association between medication use and key #PatientOutcomes, including #Mortality and #DiseaseProgression. 🔍 Watch now to learn about the latest findings and their potential to change patient care: https://lnkd.in/gwUtRPVN #ClinicaResearch #LiverDisease #HealthcareInnovation #LiverResearch #RealWorldEvidence #RealWorldData
-
🔍 Another great presentation highlighting the exciting data at the American College of Gastroenterology 2024 on how specific medications are impacting patients with #MASLD. This research from the #TARGETNASH cohort is paving the way for better treatments and improved patient outcomes! 📽️ Watch Dr. Barritt's full presentation here: https://lnkd.in/e_CcmDX8 #LiverResearch #ClinicalInnovation #RealWorldData #PatientOutcomes #HealthcareAdvances #TargetRWE #ACG2024
▶️📈 Exciting Research from #TargetRWE at #ACG2024! A. Sidney Barritt IV, MD, MSCR, lead author and member of the #TARGETNASH steering committee, presented groundbreaking findings at the American College of Gastroenterology 2024 on the real-world impact of specific medications in patients with #MASLD. In this presentation, Dr. Barritt shares insights from the TARGET-NASH cohort, exploring the association between medication use and key #PatientOutcomes, including #Mortality and #DiseaseProgression. 🔍 Watch now to learn about the latest findings and their potential to change patient care: https://lnkd.in/gwUtRPVN #ClinicaResearch #LiverDisease #HealthcareInnovation #LiverResearch #RealWorldEvidence #RealWorldData
-
22+ Years Building Strategic Partnerships Focused on Primary & Secondary Healthcare Data Use Across Product Lifecycle *** Executive Operations Leader Building Effective Teams Working Across Functional Lines
🔍 Dr. A. Sidney Barritt IV presented new, exciting data at the American College of Gastroenterology 2024 on how specific medications are impacting patients with #MASLD. This research from the #TARGETNASH cohort is paving the way for better treatments and improved patient outcomes! 📽️ Watch Dr. Barritt's full presentation here: https://lnkd.in/eqRYzPkk #LiverResearch #ClinicalInnovation #RealWorldData #PatientOutcomes #HealthcareAdvances #TargetRWE #ACG2024
▶️📈 Exciting Research from #TargetRWE at #ACG2024! A. Sidney Barritt IV, MD, MSCR, lead author and member of the #TARGETNASH steering committee, presented groundbreaking findings at the American College of Gastroenterology 2024 on the real-world impact of specific medications in patients with #MASLD. In this presentation, Dr. Barritt shares insights from the TARGET-NASH cohort, exploring the association between medication use and key #PatientOutcomes, including #Mortality and #DiseaseProgression. 🔍 Watch now to learn about the latest findings and their potential to change patient care: https://lnkd.in/gwUtRPVN #ClinicaResearch #LiverDisease #HealthcareInnovation #LiverResearch #RealWorldEvidence #RealWorldData
-
What an inspirational week at #ACR2024! Connecting with healthcare professionals across rheumatology gave us valuable insights into their challenges and helped spark new ideas to support patients. In partnership with healthcare professionals, we’re developing solutions to better meet the needs of people living with rheumatic conditions. Our commitment to advancing patient care has never been stronger. 🔗 Discover more about UCB’s collaborative approach to care: https://lnkd.in/eGd65S6Z #rheumatology #UCB #collaboration
-
What is the treatment schedule for #ruxolitinib in patients with MPNs, and how should response be assessed? 🤔 🩸 🎥 This important question was answered by Aaron Gerds, MD, MS, Cleveland Clinic in a recent interview In patients with #myelofibrosis (MF), the Response to #Ruxolitinib After 6 Months (RR6) prognostic model has been developed to allow physicians to determine which #ruxolitinib-treated patients are exhibiting sub-optimal responses to the agent and may benefit from a treatment shift 🔦 Learn more 👉 https://lnkd.in/eEQCewaF #MPNsm #VJHemOnc #MPNWorkshopNC #Hematologynews
